APO Research
Talk to an analyst

APO RESEARCH · REPORT

Corticosteroids Inhalation Formulation

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Corticosteroids Inhalation Formulation Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

24 December 2025191 pages

Choose your research edition.

Industry ResearchCorticosteroids Inhalation Formulation Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Corticosteroids Inhalation Formulation Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Corticosteroids Inhalation Formulation Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Corticosteroids Inhalation Formulation Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Corticosteroids Inhalation Formulation Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Corticosteroids Inhalation Formulation market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Corticosteroids Inhalation Formulation is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Corticosteroids Inhalation Formulation is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Corticosteroids Inhalation Formulation is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Corticosteroids Inhalation Formulation is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Corticosteroids Inhalation Formulation include Novartis, Merck, GSK, AstraZeneca, Viatris, Teva Respiratory, Recipharm AB, Perrigo and Organon Group, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Corticosteroids Inhalation Formulation market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Corticosteroids Inhalation Formulation and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Corticosteroids Inhalation Formulation sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Corticosteroids Inhalation Formulation market size, projected growth trends, production technologies, key applications, and end-use industries.

Corticosteroids Inhalation Formulation Segment by Company

Novartis

Merck

GSK

AstraZeneca

Viatris

Teva Respiratory

Recipharm AB

Perrigo

Organon Group

Lupin

Cipla

Boehringer Ingelheim International

Corticosteroids Inhalation Formulation Segment by Type

Beclomethasone

Budesonide

Fluticasone

Mometasone Furoate

Other

Corticosteroids Inhalation Formulation Segment by Application

Specialty Clinics

Hospitals

Online Pharmacies

Retail Pharmacy Chains

Other

Corticosteroids Inhalation Formulation Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Corticosteroids Inhalation Formulation market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Corticosteroids Inhalation Formulation and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Corticosteroids Inhalation Formulation.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Corticosteroids Inhalation Formulation market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Corticosteroids Inhalation Formulation manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Corticosteroids Inhalation Formulation in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Corticosteroids Inhalation Formulation in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Corticosteroids Inhalation Formulation Industry Trends Table 2. Corticosteroids Inhalation Formulation Industry Drivers Table 3. Corticosteroids Inhalation Formulation Industry Opportunities and Challenges Table 4. Corticosteroids Inhalation Formulation Industry Restraints Table 5. Global Corticosteroids Inhalation Formulation Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Corticosteroids Inhalation Formulation Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Corticosteroids Inhalation Formulation Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Corticosteroids Inhalation Formulation Sales Market Share by Manufacturers Table 9. Global Corticosteroids Inhalation Formulation Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Corticosteroids Inhalation Formulation Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Corticosteroids Inhalation Formulation Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Corticosteroids Inhalation Formulation Manufacturers, Product Type & Application Table 13. Global Corticosteroids Inhalation Formulation Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Corticosteroids Inhalation Formulation by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Beclomethasone Table 17. Major Manufacturers of Budesonide Table 18. Major Manufacturers of Fluticasone Table 19. Major Manufacturers of Mometasone Furoate Table 20. Major Manufacturers of Other Table 21. Global Corticosteroids Inhalation Formulation Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Corticosteroids Inhalation Formulation Sales by Type (2021-2026) & (K Units) Table 23. Global Corticosteroids Inhalation Formulation Sales by Type (2027-2032) & (K Units) Table 24. Global Corticosteroids Inhalation Formulation Sales Market Share by Type (2021-2026) Table 25. Global Corticosteroids Inhalation Formulation Sales Market Share by Type (2027-2032) Table 26. Global Corticosteroids Inhalation Formulation Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Corticosteroids Inhalation Formulation Revenue by Type (2021-2026) & (K Units) Table 28. Global Corticosteroids Inhalation Formulation Revenue by Type (2027-2032) & (K Units) Table 29. Global Corticosteroids Inhalation Formulation Revenue Market Share by Type (2021-2026) Table 30. Global Corticosteroids Inhalation Formulation Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Specialty Clinics Table 32. Major Manufacturers of Hospitals Table 33. Major Manufacturers of Online Pharmacies Table 34. Major Manufacturers of Retail Pharmacy Chains Table 35. Major Manufacturers of Other Table 36. Global Corticosteroids Inhalation Formulation Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Corticosteroids Inhalation Formulation Sales by Application (2021-2026) & (K Units) Table 38. Global Corticosteroids Inhalation Formulation Sales by Application (2027-2032) & (K Units) Table 39. Global Corticosteroids Inhalation Formulation Sales Market Share by Application (2021-2026) Table 40. Global Corticosteroids Inhalation Formulation Sales Market Share by Application (2027-2032) Table 41. Global Corticosteroids Inhalation Formulation Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 42. Global Corticosteroids Inhalation Formulation Revenue by Application (2021-2026) & (K Units) Table 43. Global Corticosteroids Inhalation Formulation Revenue by Application (2027-2032) & (K Units) Table 44. Global Corticosteroids Inhalation Formulation Revenue Market Share by Application (2021-2026) Table 45. Global Corticosteroids Inhalation Formulation Revenue Market Share by Application (2027-2032) Table 46. Global Corticosteroids Inhalation Formulation Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Corticosteroids Inhalation Formulation Sales by Region (2021-2026) & (K Units) Table 48. Global Corticosteroids Inhalation Formulation Sales Market Share by Region (2021-2026) Table 49. Global Corticosteroids Inhalation Formulation Sales Forecasted by Region (2027-2032) & (K Units) Table 50. Global Corticosteroids Inhalation Formulation Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Corticosteroids Inhalation Formulation Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. North America Corticosteroids Inhalation Formulation Sales by Country (2021-2026) & (K Units) Table 53. North America Corticosteroids Inhalation Formulation Sales by Country (2027-2032) & (K Units) Table 54. Europe Corticosteroids Inhalation Formulation Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Europe Corticosteroids Inhalation Formulation Sales by Country (2021-2026) & (K Units) Table 56. Europe Corticosteroids Inhalation Formulation Sales by Country (2027-2032) & (K Units) Table 57. Asia Pacific Corticosteroids Inhalation Formulation Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Asia Pacific Corticosteroids Inhalation Formulation Sales by Country (2021-2026) & (K Units) Table 59. Asia Pacific Corticosteroids Inhalation Formulation Sales by Country (2027-2032) & (K Units) Table 60. South America, Middle East and Africa Corticosteroids Inhalation Formulation Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. South America, Middle East and Africa Corticosteroids Inhalation Formulation Sales by Country (2021-2026) & (K Units) Table 62. South America, Middle East and Africa Corticosteroids Inhalation Formulation Sales by Country (2027-2032) & (K Units) Table 63. Global Corticosteroids Inhalation Formulation Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Corticosteroids Inhalation Formulation Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Corticosteroids Inhalation Formulation Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Corticosteroids Inhalation Formulation Revenue Market Share by Region (2021-2026) Table 67. Global Corticosteroids Inhalation Formulation Revenue Market Share by Region (2027-2032) Table 68. Novartis Company Information Table 69. Novartis Business Overview Table 70. Novartis Corticosteroids Inhalation Formulation Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Novartis Corticosteroids Inhalation Formulation Product Portfolio Table 72. Novartis Recent Development Table 73. Merck Company Information Table 74. Merck Business Overview Table 75. Merck Corticosteroids Inhalation Formulation Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Merck Corticosteroids Inhalation Formulation Product Portfolio Table 77. Merck Recent Development Table 78. GSK Company Information Table 79. GSK Business Overview Table 80. GSK Corticosteroids Inhalation Formulation Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. GSK Corticosteroids Inhalation Formulation Product Portfolio Table 82. GSK Recent Development Table 83. AstraZeneca Company Information Table 84. AstraZeneca Business Overview Table 85. AstraZeneca Corticosteroids Inhalation Formulation Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. AstraZeneca Corticosteroids Inhalation Formulation Product Portfolio Table 87. AstraZeneca Recent Development Table 88. Viatris Company Information Table 89. Viatris Business Overview Table 90. Viatris Corticosteroids Inhalation Formulation Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Viatris Corticosteroids Inhalation Formulation Product Portfolio Table 92. Viatris Recent Development Table 93. Teva Respiratory Company Information Table 94. Teva Respiratory Business Overview Table 95. Teva Respiratory Corticosteroids Inhalation Formulation Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Teva Respiratory Corticosteroids Inhalation Formulation Product Portfolio Table 97. Teva Respiratory Recent Development Table 98. Recipharm AB Company Information Table 99. Recipharm AB Business Overview Table 100. Recipharm AB Corticosteroids Inhalation Formulation Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Recipharm AB Corticosteroids Inhalation Formulation Product Portfolio Table 102. Recipharm AB Recent Development Table 103. Perrigo Company Information Table 104. Perrigo Business Overview Table 105. Perrigo Corticosteroids Inhalation Formulation Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Perrigo Corticosteroids Inhalation Formulation Product Portfolio Table 107. Perrigo Recent Development Table 108. Organon Group Company Information Table 109. Organon Group Business Overview Table 110. Organon Group Corticosteroids Inhalation Formulation Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Organon Group Corticosteroids Inhalation Formulation Product Portfolio Table 112. Organon Group Recent Development Table 113. Lupin Company Information Table 114. Lupin Business Overview Table 115. Lupin Corticosteroids Inhalation Formulation Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Lupin Corticosteroids Inhalation Formulation Product Portfolio Table 117. Lupin Recent Development Table 118. Cipla Company Information Table 119. Cipla Business Overview Table 120. Cipla Corticosteroids Inhalation Formulation Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Cipla Corticosteroids Inhalation Formulation Product Portfolio Table 122. Cipla Recent Development Table 123. Boehringer Ingelheim International Company Information Table 124. Boehringer Ingelheim International Business Overview Table 125. Boehringer Ingelheim International Corticosteroids Inhalation Formulation Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Boehringer Ingelheim International Corticosteroids Inhalation Formulation Product Portfolio Table 127. Boehringer Ingelheim International Recent Development Table 128. Key Raw Materials Table 129. Raw Materials Key Suppliers Table 130. Corticosteroids Inhalation Formulation Distributors List Table 131. Corticosteroids Inhalation Formulation Customers List Table 132. Research Programs/Design for This Report Table 133. Authors List of This Report Table 134. Secondary Sources Table 135. Primary Sources List of Figures Figure 1. Corticosteroids Inhalation Formulation Product Image Figure 2. Global Corticosteroids Inhalation Formulation Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Corticosteroids Inhalation Formulation Market Size (2021-2032) & (US$ Million) Figure 4. Global Corticosteroids Inhalation Formulation Sales (2021-2032) & (K Units) Figure 5. Global Corticosteroids Inhalation Formulation Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Corticosteroids Inhalation Formulation Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Beclomethasone Image Figure 9. Budesonide Image Figure 10. Fluticasone Image Figure 11. Mometasone Furoate Image Figure 12. Other Image Figure 13. Global Corticosteroids Inhalation Formulation Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Corticosteroids Inhalation Formulation Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Corticosteroids Inhalation Formulation Sales Market Share by Type (2021-2032) Figure 16. Global Corticosteroids Inhalation Formulation Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Corticosteroids Inhalation Formulation Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Corticosteroids Inhalation Formulation Revenue Market Share by Type (2021-2032) Figure 19. Specialty Clinics Image Figure 20. Hospitals Image Figure 21. Online Pharmacies Image Figure 22. Retail Pharmacy Chains Image Figure 23. Other Image Figure 24. Global Corticosteroids Inhalation Formulation Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Corticosteroids Inhalation Formulation Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Corticosteroids Inhalation Formulation Sales Market Share by Application (2021-2032) Figure 27. Global Corticosteroids Inhalation Formulation Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 28. Global Corticosteroids Inhalation Formulation Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Corticosteroids Inhalation Formulation Revenue Market Share by Application (2021-2032) Figure 30. North America Corticosteroids Inhalation Formulation Sales and Growth Rate (2021-2032) & (K Units) Figure 31. North America Corticosteroids Inhalation Formulation Sales Market Share by Country (2021-2032) Figure 32. U.S. Corticosteroids Inhalation Formulation Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Canada Corticosteroids Inhalation Formulation Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Mexico Corticosteroids Inhalation Formulation Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Corticosteroids Inhalation Formulation Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Europe Corticosteroids Inhalation Formulation Sales Market Share by Country (2021-2032) Figure 37. Germany Corticosteroids Inhalation Formulation Sales and Growth Rate (2021-2032) & (K Units) Figure 38. France Corticosteroids Inhalation Formulation Sales and Growth Rate (2021-2032) & (K Units) Figure 39. U.K. Corticosteroids Inhalation Formulation Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Italy Corticosteroids Inhalation Formulation Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Netherlands Corticosteroids Inhalation Formulation Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Corticosteroids Inhalation Formulation Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Asia Pacific Corticosteroids Inhalation Formulation Sales Market Share by Country (2021-2032) Figure 44. China Corticosteroids Inhalation Formulation Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Japan Corticosteroids Inhalation Formulation Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South Korea Corticosteroids Inhalation Formulation Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Southeast Asia Corticosteroids Inhalation Formulation Sales and Growth Rate (2021-2032) & (K Units) Figure 48. India Corticosteroids Inhalation Formulation Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Australia Corticosteroids Inhalation Formulation Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Corticosteroids Inhalation Formulation Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South America, Middle East and Africa Corticosteroids Inhalation Formulation Sales Market Share by Country (2021-2032) Figure 52. Brazil Corticosteroids Inhalation Formulation Sales and Growth Rate (2021-2032) & (K Units) Figure 53. South Africa Corticosteroids Inhalation Formulation Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Saudi Arabia Corticosteroids Inhalation Formulation Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Turkey Corticosteroids Inhalation Formulation Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Argentina Corticosteroids Inhalation Formulation Sales and Growth Rate (2021-2032) & (K Units) Figure 57. UAE Corticosteroids Inhalation Formulation Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Egypt Corticosteroids Inhalation Formulation Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Chile Corticosteroids Inhalation Formulation Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Global Corticosteroids Inhalation Formulation Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Corticosteroids Inhalation Formulation Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Corticosteroids Inhalation Formulation Revenue (2021-2032) & (US$ Million) Figure 63. North America Corticosteroids Inhalation Formulation Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Corticosteroids Inhalation Formulation Revenue (2021-2032) & (US$ Million) Figure 65. Europe Corticosteroids Inhalation Formulation Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Corticosteroids Inhalation Formulation Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Corticosteroids Inhalation Formulation Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Corticosteroids Inhalation Formulation Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Corticosteroids Inhalation Formulation Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Corticosteroids Inhalation Formulation Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Corticosteroids Inhalation Formulation Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Beclomethasone
  • Budesonide
  • Fluticasone
  • Mometasone Furoate
  • Other
Applications
  • Specialty Clinics
  • Hospitals
  • Online Pharmacies
  • Retail Pharmacy Chains
  • Other
Companies covered
  • Novartis
  • Merck
  • GSK
  • AstraZeneca
  • Viatris
  • Teva Respiratory
  • Recipharm AB
  • Perrigo
  • Organon Group
  • Lupin
  • Cipla
  • Boehringer Ingelheim International

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Corticosteroids Inhalation Formulation Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Corticosteroids Inhalation Formulation Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Corticosteroids Inhalation Formulation Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Corticosteroids Inhalation Formulation Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Corticosteroids Inhalation Formulation Market Dynamics
  1. 2.1 Corticosteroids Inhalation Formulation Industry Trends
  2. 2.2 Corticosteroids Inhalation Formulation Industry Drivers
  3. 2.3 Corticosteroids Inhalation Formulation Industry Opportunities and Challenges
  4. 2.4 Corticosteroids Inhalation Formulation Industry Restraints
3 Corticosteroids Inhalation Formulation Market by Manufacturers
  1. 3.1 Global Corticosteroids Inhalation Formulation Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Corticosteroids Inhalation Formulation Sales by Manufacturers (2021-2026)
  3. 3.3 Global Corticosteroids Inhalation Formulation Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Corticosteroids Inhalation Formulation Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Corticosteroids Inhalation Formulation Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Corticosteroids Inhalation Formulation Manufacturers, Product Type & Application
  7. 3.7 Global Corticosteroids Inhalation Formulation Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Corticosteroids Inhalation Formulation Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Corticosteroids Inhalation Formulation Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Corticosteroids Inhalation Formulation Tier 1, Tier 2, and Tier 3
4 Corticosteroids Inhalation Formulation Market by Type
  1. 4.1 Corticosteroids Inhalation Formulation Type Introduction
  2. 4.1.1 Beclomethasone
  3. 4.1.2 Budesonide
  4. 4.1.3 Fluticasone
  5. 4.1.4 Mometasone Furoate
  6. 4.1.5 Other
  7. 4.2 Global Corticosteroids Inhalation Formulation Sales by Type
  8. 4.2.1 Global Corticosteroids Inhalation Formulation Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Corticosteroids Inhalation Formulation Sales by Type (2021-2032)
  10. 4.2.3 Global Corticosteroids Inhalation Formulation Sales Market Share by Type (2021-2032)
  11. 4.3 Global Corticosteroids Inhalation Formulation Revenue by Type
  12. 4.3.1 Global Corticosteroids Inhalation Formulation Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Corticosteroids Inhalation Formulation Revenue by Type (2021-2032)
  14. 4.3.3 Global Corticosteroids Inhalation Formulation Revenue Market Share by Type (2021-2032)
5 Corticosteroids Inhalation Formulation Market by Application
  1. 5.1 Corticosteroids Inhalation Formulation Application Introduction
  2. 5.1.1 Specialty Clinics
  3. 5.1.2 Hospitals
  4. 5.1.3 Online Pharmacies
  5. 5.1.4 Retail Pharmacy Chains
  6. 5.1.5 Other
  7. 5.2 Global Corticosteroids Inhalation Formulation Sales by Application
  8. 5.2.1 Global Corticosteroids Inhalation Formulation Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Corticosteroids Inhalation Formulation Sales by Application (2021-2032)
  10. 5.2.3 Global Corticosteroids Inhalation Formulation Sales Market Share by Application (2021-2032)
  11. 5.3 Global Corticosteroids Inhalation Formulation Revenue by Application
  12. 5.3.1 Global Corticosteroids Inhalation Formulation Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Corticosteroids Inhalation Formulation Revenue by Application (2021-2032)
  14. 5.3.3 Global Corticosteroids Inhalation Formulation Revenue Market Share by Application (2021-2032)
6 Global Corticosteroids Inhalation Formulation Sales by Region
  1. 6.1 Global Corticosteroids Inhalation Formulation Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Corticosteroids Inhalation Formulation Sales by Region (2021-2032)
  3. 6.2.1 Global Corticosteroids Inhalation Formulation Sales by Region (2021-2026)
  4. 6.2.2 Global Corticosteroids Inhalation Formulation Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Corticosteroids Inhalation Formulation Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Corticosteroids Inhalation Formulation Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Corticosteroids Inhalation Formulation Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Corticosteroids Inhalation Formulation Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Corticosteroids Inhalation Formulation Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Corticosteroids Inhalation Formulation Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Corticosteroids Inhalation Formulation Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Corticosteroids Inhalation Formulation Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Corticosteroids Inhalation Formulation Revenue by Region
  1. 7.1 Global Corticosteroids Inhalation Formulation Revenue by Region
  2. 7.1.1 Global Corticosteroids Inhalation Formulation Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Corticosteroids Inhalation Formulation Revenue by Region (2021-2026)
  4. 7.1.3 Global Corticosteroids Inhalation Formulation Revenue by Region (2027-2032)
  5. 7.1.4 Global Corticosteroids Inhalation Formulation Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Corticosteroids Inhalation Formulation Revenue (2021-2032)
  8. 7.2.2 North America Corticosteroids Inhalation Formulation Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Corticosteroids Inhalation Formulation Revenue (2021-2032)
  11. 7.3.2 Europe Corticosteroids Inhalation Formulation Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Corticosteroids Inhalation Formulation Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Corticosteroids Inhalation Formulation Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Corticosteroids Inhalation Formulation Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Corticosteroids Inhalation Formulation Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Corticosteroids Inhalation Formulation Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Corticosteroids Inhalation Formulation Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Corticosteroids Inhalation Formulation Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck Corticosteroids Inhalation Formulation Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 GSK
  14. 8.3.1 GSK Company Information
  15. 8.3.2 GSK Business Overview
  16. 8.3.3 GSK Corticosteroids Inhalation Formulation Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 GSK Corticosteroids Inhalation Formulation Product Portfolio
  18. 8.3.5 GSK Recent Developments
  19. 8.4 AstraZeneca
  20. 8.4.1 AstraZeneca Company Information
  21. 8.4.2 AstraZeneca Business Overview
  22. 8.4.3 AstraZeneca Corticosteroids Inhalation Formulation Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 AstraZeneca Corticosteroids Inhalation Formulation Product Portfolio
  24. 8.4.5 AstraZeneca Recent Developments
  25. 8.5 Viatris
  26. 8.5.1 Viatris Company Information
  27. 8.5.2 Viatris Business Overview
  28. 8.5.3 Viatris Corticosteroids Inhalation Formulation Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Viatris Corticosteroids Inhalation Formulation Product Portfolio
  30. 8.5.5 Viatris Recent Developments
  31. 8.6 Teva Respiratory
  32. 8.6.1 Teva Respiratory Company Information
  33. 8.6.2 Teva Respiratory Business Overview
  34. 8.6.3 Teva Respiratory Corticosteroids Inhalation Formulation Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Teva Respiratory Corticosteroids Inhalation Formulation Product Portfolio
  36. 8.6.5 Teva Respiratory Recent Developments
  37. 8.7 Recipharm AB
  38. 8.7.1 Recipharm AB Company Information
  39. 8.7.2 Recipharm AB Business Overview
  40. 8.7.3 Recipharm AB Corticosteroids Inhalation Formulation Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Recipharm AB Corticosteroids Inhalation Formulation Product Portfolio
  42. 8.7.5 Recipharm AB Recent Developments
  43. 8.8 Perrigo
  44. 8.8.1 Perrigo Company Information
  45. 8.8.2 Perrigo Business Overview
  46. 8.8.3 Perrigo Corticosteroids Inhalation Formulation Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Perrigo Corticosteroids Inhalation Formulation Product Portfolio
  48. 8.8.5 Perrigo Recent Developments
  49. 8.9 Organon Group
  50. 8.9.1 Organon Group Company Information
  51. 8.9.2 Organon Group Business Overview
  52. 8.9.3 Organon Group Corticosteroids Inhalation Formulation Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Organon Group Corticosteroids Inhalation Formulation Product Portfolio
  54. 8.9.5 Organon Group Recent Developments
  55. 8.10 Lupin
  56. 8.10.1 Lupin Company Information
  57. 8.10.2 Lupin Business Overview
  58. 8.10.3 Lupin Corticosteroids Inhalation Formulation Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Lupin Corticosteroids Inhalation Formulation Product Portfolio
  60. 8.10.5 Lupin Recent Developments
  61. 8.11 Cipla
  62. 8.11.1 Cipla Company Information
  63. 8.11.2 Cipla Business Overview
  64. 8.11.3 Cipla Corticosteroids Inhalation Formulation Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Cipla Corticosteroids Inhalation Formulation Product Portfolio
  66. 8.11.5 Cipla Recent Developments
  67. 8.12 Boehringer Ingelheim International
  68. 8.12.1 Boehringer Ingelheim International Company Information
  69. 8.12.2 Boehringer Ingelheim International Business Overview
  70. 8.12.3 Boehringer Ingelheim International Corticosteroids Inhalation Formulation Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Boehringer Ingelheim International Corticosteroids Inhalation Formulation Product Portfolio
  72. 8.12.5 Boehringer Ingelheim International Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Corticosteroids Inhalation Formulation Value Chain Analysis
  2. 9.1.1 Corticosteroids Inhalation Formulation Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Corticosteroids Inhalation Formulation Production Mode & Process
  6. 9.2 Corticosteroids Inhalation Formulation Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Corticosteroids Inhalation Formulation Distributors
  9. 9.2.3 Corticosteroids Inhalation Formulation Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst